← All trials
NCT07168278
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2025
- Primary completion
- Mar 1, 2028
- Completion date
- May 31, 2028
- First posted
- Sep 11, 2025
- Last posted
- Sep 11, 2025
- Enrollment
- 794
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of Science and Technology of ChinaLead sponsor
- University of Science and Technology of ChinaSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.